Can I Take Reishi Mushroom with Provigil (Modafinil)?

The direct answer

There is no confirmed clinical interaction between reishi mushroom and modafinil, and no controlled human study has looked for one. The theoretical risk comes from two separate mechanisms: possible CYP3A4 enzyme inhibition by reishi triterpenes, which could slow modafinil clearance, and reishi's antiplatelet activity, which could compound bleeding risk in someone also taking a blood thinner. For a typical modafinil user without anticoagulant use or liver disease, the evidence does not show a documented pattern of harm from this combination, but the absence of trial data means an individual reaction cannot be ruled out. Disclosure to the prescriber and a period of self-monitoring is the reasonable approach given the current state of evidence.

Why this combination raises a question at all

Modafinil is FDA-approved for narcolepsy, as an adjunct for obstructive sleep apnea, and for shift-work sleep disorder. Full prescribing information, including its metabolism and drug-interaction section, is in the current FDA label (accessdata.fda.gov).

Reishi mushroom (Ganoderma lucidum) is a fungus used for centuries in traditional Chinese medicine and now sold widely as an immune-support and general wellness supplement. In the U.S. it is regulated as a dietary supplement, not a drug, which means it has not gone through FDA review for safety or efficacy and carries no FDA-mandated interaction labeling. A concise overview of its traditional use, chemistry, and reported bioactivities is available through the National Institutes of Health's book chapter on medicinal mushrooms (NCBI Bookshelf).

The interaction question is a pharmacology inference, not an observed clinical event: modafinil is cleared in part through the CYP3A4 enzyme system, and reishi contains triterpene compounds (ganoderic acids) that laboratory studies have reported can inhibit CYP3A4 activity. Separately, reishi has a body of literature, including at least one published case report, describing antiplatelet or bleeding effects. Neither line of evidence has been tested in a trial that combines the two substances in humans, so the size and clinical relevance of any interaction is unknown rather than small or large.

What is established, what is plausible, and what is not established

Evidence-status interaction assessment

Refer to this table when discussing modafinil interactions with your pharmacist or doctor, but don't rely on it in place of professional medical advice. For combinations marked "not established," any definitive assertions about safety or risk lack sufficient evidence.

Who should treat this more cautiously

Three groups carry a higher theoretical burden of risk:

• People on anticoagulants or antiplatelet drugs (warfarin, apixaban, rivaroxaban, aspirin, clopidogrel). Reishi's antiplatelet activity, if it applies to the individual product and dose taken, would add to an already-present bleeding risk. This is the one scenario where proactive discussion with a prescriber, rather than watchful waiting, is the sensible default.
• People with hepatic impairment. Both modafinil clearance and any reishi-related enzyme effect run through the liver; reduced hepatic function narrows the safety margin for either substance alone, let alone in combination.
• People taking other CYP3A4-dependent medications (certain immunosuppressants, some statins, some hormonal contraceptives). Adding a compound with reported CYP3A4 activity introduces another variable into an already sensitive metabolic pathway.

Outside these groups, at typical modafinil doses (100 to 200 mg per day) and moderate reishi supplement use, the evidence does not point to a documented pattern of harm, but "no documented harm" reflects the absence of trial data as much as it reflects reassurance.

Practical steps if you are taking or considering both

Tell your prescriber, and be specific about the product

Bring the exact reishi product (brand, extract type, dose, whether it is fruiting-body or mycelium-based) to your next visit. Product variability is a real practical issue: dietary supplements are not required to demonstrate consistent active-ingredient content the way FDA-approved drugs are, and the reishi supplement market has a documented history of quality-consistency concerns. A specific percentage or product-count figure describing how many tested products contained detectable Ganoderma material should be verified against the original study before being treated as current or precise; the general point that quality varies across brands is on firmer footing than any single number.

Consider separating the doses

If you and your prescriber decide to continue both, taking modafinil in the morning and reishi later in the day reduces peak overlap in the bloodstream. This is a reasonable precaution rather than a proven risk-elimination step, since both substances have long durations of activity and dose separation does not eliminate a true enzyme-level interaction if one exists.

Start reishi at a low dose if adding it to an existing modafinil regimen

Starting at the lowest available dose and holding there for one to two weeks before increasing gives you a window to notice any change before stacking further variables.

Watch for specific signals in the first 30 days

• Unusual bruising, nosebleeds, or bleeding from minor cuts that takes longer than usual to stop
• Insomnia that is clearly worse than your baseline modafinil experience, or a sense of being "overstimulated"
• New or worsening headache, or a resting heart rate meaningfully above your baseline
• Gastrointestinal upset (nausea, dry mouth), which is a recognized reishi side effect independent of any interaction

Get an INR check if you take warfarin

If you take warfarin and add reishi, checking INR within one to two weeks of starting is a reasonable safety step, given reishi's documented antiplatelet signal and warfarin's narrow therapeutic window. This is a site-judgment recommendation based on general anticoagulant-monitoring practice, not a study that tested reishi and warfarin together with modafinil present.

What to do if you have already been taking both without problems

Many people combine supplements and prescription medications for months before ever asking whether it is a problem, and the theoretical (not confirmed) nature of this interaction means that absence of symptoms is meaningfully reassuring, though not a guarantee. If you feel fine, mention the combination at your next visit rather than stopping anything abruptly. If you notice new symptoms consistent with the list above, stop the reishi supplement first, since it is the newer and less essential variable, and contact your prescriber. Seek urgent care for significant unexplained bleeding, a heart rate sustained well above your baseline, or new neurological symptoms.

Evidence boundary

Established: Modafinil's FDA-approved indications and its partial CYP3A4-dependent metabolism are documented in its prescribing information. Reishi is regulated as a dietary supplement in the U.S. with no FDA-approved medical indication and no mandated interaction labeling.

Plausible but unproven: Laboratory (in vitro) evidence supports the idea that reishi triterpenes can inhibit CYP3A4 and that reishi compounds have antiplatelet activity. Whether either effect reaches a clinically meaningful magnitude at typical oral supplement doses, in combination with modafinil specifically, has not been tested.

Not established: No published human pharmacokinetic study has measured modafinil levels with and without concurrent reishi. No controlled trial or case series documents a clinical bleeding or overstimulation event from this specific combination. Any precise number describing enzyme inhibition potency, bleeding incidence, or supplement adulteration rates should be checked against the original primary study before being repeated as fact; several such figures could not be independently verified for this draft and are described here only in general terms.

Note for editorial and medical review: several claims inherited from the prior draft, including specific enzyme IC50 values, a named case report, a supplement-adulteration percentage, and two attributed quotations, could not be verified against a confirmed primary source during this revision and have been rewritten as general statements or removed. Please verify against current primary literature before restoring any specific figure or quotation.